Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences Inc (NASDAQ: PCRX) is a leader in non-opioid pain management, offering innovative therapies that reduce reliance on traditional opioids. This page provides investors and healthcare professionals with timely updates on the company’s latest developments, including regulatory milestones, clinical advancements, and strategic initiatives.
Access PCRX’s official press releases, earnings reports, and analysis of key events shaping its position in the specialty pharmaceutical sector. Track updates on flagship products like EXPAREL® (long-acting local anesthetic) and iovera® (targeted cold therapy), along with emerging pipeline candidates such as PCRX-201 for osteoarthritis.
Discover how Pacira’s proprietary drug delivery platforms and commitment to evidence-based solutions address critical needs in postsurgical recovery and chronic pain management. Stay informed about partnerships, regulatory approvals, and market expansion efforts driving the company’s growth.
Bookmark this page for direct access to PCRX’s verified news, ensuring you never miss developments impacting its role in transforming pain treatment. Visit regularly to monitor progress in non-opioid innovation and regenerative health solutions.
Pacira BioSciences (Nasdaq: PCRX) announced record net product sales of EXPAREL totaling $51.2 million for March 2022, reflecting a 116% increase over March 2021. For Q1 2022, preliminary revenues range from $157.4 million to $158.4 million, up from $119.0 million in Q1 2021. Sales of ZILRETTA are estimated between $23.0 million and $24.0 million, down slightly from $24.6 million in Q1 2021. The company is not providing full-year 2022 revenue guidance due to ongoing uncertainties related to COVID-19's impact on elective surgeries.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 AM ET. Interested parties can access the live audio on the company’s events page. A replay will be available for two weeks post-event.
Pacira focuses on providing non-opioid treatment options for patients, with commercial-stage products like EXPAREL®, ZILRETTA®, and ioveraº®. The company aims to redefine opioid use and addresses conditions involving the sympathetic nervous system.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for EXPAREL and iovera° for February 2022. EXPAREL sales reached $41.7 million, an increase of 17.2% from $35.6 million in February 2021, indicating average daily sales at 117% of the previous year. iovera° sales rose to $0.9 million, up from $0.7 million. The company noted ongoing challenges due to the COVID-19 pandemic impacting elective surgeries but did not provide financial guidance for 2022 due to uncertainties.
TAMPA, Fla., March 09, 2022 — Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 AM ET in Miami. Investors can listen to the live audio via the company's Events page, with a replay available for two weeks post-event. Pacira focuses on non-opioid treatments, offering products like EXPAREL for postsurgical pain management and ZILRETTA for osteoarthritis knee pain, aiming to reduce opioid reliance.
Pacira BioSciences (PCRX) reported record EXPAREL sales of $507 million for 2021, contributing to total revenues of $541.5 million, a 26% increase from 2020. The company achieved a GAAP net income of $42 million ($0.95 per share) but faced a GAAP net loss of $5.1 million in Q4 2021. Adjusted EBITDA for the year rose to $204 million. The acquisition of Flexion Therapeutics bolstered its non-opioid pain management portfolio. Looking ahead, Pacira refrained from providing 2022 revenue guidance due to ongoing COVID-19 impacts on elective surgeries.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and year-end financial results for December 31, 2021, on February 24, 2022, prior to market opening. A live conference call and webcast will follow at 8:30 a.m. ET, allowing participants to engage directly. Interested parties can access the event through the company’s investor webpage. Pacira focuses on non-opioid pain management solutions and has three commercial products: EXPAREL, ZILRETTA, and iovera, aimed at reducing opioid dependency in pain treatment.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net product sales for EXPAREL and iovera° for January 2022. EXPAREL's net sales reached $36.3 million, a 4% increase from January 2021, with average daily sales at 104% of the previous year. Iovera° sales remained steady at $1.1 million. CEO Dave Stack reported growth trends for EXPAREL and the ongoing launch of the next-generation iovera° device. However, the company did not provide 2022 financial guidance due to ongoing uncertainty surrounding COVID-19's impact on elective surgeries.
Pacira BioSciences (Nasdaq: PCRX) reported record net product sales of $506.5 million for 2021, marking a 25.8% increase from 2020. Fourth quarter sales of EXPAREL reached $139.9 million, driven by strong growth, although affected by COVID-19-related restrictions in December. The company also recognized sales of ZILRETTA and iovera°, contributing to total revenue of $540.7 million to $541.7 million for the year. Despite challenges posed by the pandemic, Pacira remains optimistic about future growth in non-opioid pain management solutions.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 PM ET. Interested parties can access the live audio via the company's website, with a replay available for two weeks post-event. Pacira is dedicated to providing non-opioid pain management solutions and has three commercial-stage products: EXPAREL®, ZILRETTA®, and ioveraº®. Their mission focuses on reducing reliance on opioids and developing innovative treatments for chronic pain and related conditions.
Pacira BioSciences (Nasdaq: PCRX) has successfully closed a $375 million Senior Secured Term Loan B Facility, enhancing its operational and financial flexibility. The proceeds will be utilized for general corporate purposes, including replenishing funds from the recent acquisition of Flexion Therapeutics and repaying existing convertible senior notes. CFO Charles Reinhart emphasizes confidence in the company's forecasted earnings and operating cash flow, supporting their five-year growth plan aimed at revenue and earnings expansion.
